Immuneering Corp SEC filings IMRX
Immuneering Corp has 322 filings in SEC EDGAR's recent list, going back to Oct 4, 2019. Its latest annual report, Form 10-K, was filed on Mar 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Sep 9, 2025 | — |
| EFFECT | Filing | Sep 8, 2025 | — |
| CORRESP | Letter to the SEC | Sep 4, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2025 | — |
| EFFECT | Filing | Aug 20, 2025 | — |
| CORRESP | Letter to the SEC | Aug 18, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2025 | — |
| EFFECT | Filing | Aug 19, 2022 | — |
| CORRESP | Letter to the SEC | Aug 17, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2022 | — |
| EFFECT | Filing | Jul 29, 2021 | — |
| CORRESP | Letter to the SEC | Jul 28, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 27, 2021 | — |
| CERT | Filing | Jul 27, 2021 | — |
| CORRESP | Letter to the SEC | Jul 27, 2021 | — |
| CORRESP | Letter to the SEC | Jul 27, 2021 | — |
| 8-A12B | Filing | Jul 27, 2021 | — |
| CORRESP | Letter to the SEC | Jul 14, 2021 | — |
| CORRESP | Letter to the SEC | Jul 9, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 1, 2021 | — |
| DRSLTR | Filing | Jun 21, 2021 | — |
| DRS/A | Filing | Jun 21, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2021 | — |
| DRS | Filing | May 13, 2021 | — |
| D | Filing | Jan 5, 2021 | — |
| D/A | Filing | Jan 27, 2020 | — |
| D | Filing | Oct 4, 2019 | — |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1790340
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.